Nice's decision to withhold a breakthrough prostate cancer drug is a "cruel twist" as it comes "just days" after a study confirmed its success, campaigners have said.
Prostate Cancer UK called on Nice, who vet the cost effectiveness of medicine for NHS patients, to change its "post-chemo" policy on new drugs.
Enzalutamide is already licensed for those who've had chemotherapy but this trial will hopefully establish a robust base of evidence to demonstrate that it should be available beforehand.
This is good news but sadly won't help the one man an hour who dies of prostate cancer at present.
We need to see drugs like enzalutamide available sooner rather than later, and so it's a cruel twist that this study comes just days after Nice ruled out the drug for men who have already had chemotherapy and the only other drug available at this stage, abiraterone.
More top news
Andrew Britton recalled the horror he felt as a routine virus took a nasty turn and his joy at the son he feared he would never have.
Malicious software that can be used for long-term surveillance operations has been discovered by computer security company Symantec Corp.
A soldier who lost a leg when he was trapped in an Afghanistan minefield has spoken of the controversial rescue mission.